Panretin is used to treat skin sores in patients with a certain type of AIDS-related cancer. The U.S. is experiencing a shortage of the FDA-approved gel due to manufacturing issues.
While the FDA approved the temporary use of the European version of the drug, the product does contain different prescribing information on its label than the American version. Therefore, a copy of the FDA-approved prescribing information will be distributed with the European version of Panretin.
More articles on suppy chain:
Pfizer CEO responds to Trump’s threats against pharma: ‘We need to raise prices’
Short seller predicts Lannett will be first drugmaker to go bankrupt amid price scrutiny
Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.